Basra Sukhdeep S, Virani Salim S, Paniagua David, Kar Biswajit, Jneid Hani
Division of Cardiology, Baylor College of Medicine, Houston, TX 77030, USA.
Division of Cardiology, Baylor College of Medicine, The Michael E. DeBakey VA Medical Center, 2002 Holcombe Boulevard, Houston, TX 77030, USA.
Heart Fail Clin. 2016 Jan;12(1):31-48. doi: 10.1016/j.hfc.2015.08.004.
Non-ST elevation acute coronary syndromes (NSTE-ACS) encompass the clinical entities of unstable angina and non-ST elevation myocardial infarction. Several advances have occurred over the past decade, including the emergence of new antiplatelet and antithrombotic therapies and novel treatment strategies, leading to marked improvements in mortality. However, there has also been an increased incidence in NSTE-ACS as a result of the use of high-sensitivity troponins and the increase in cardiovascular risk factors. This article provides a focused update on contemporary management strategies pertaining to antiplatelet, antithrombotic, and anti-ischemic therapies and to revascularization strategies in patients with ACS.
非ST段抬高型急性冠状动脉综合征（NSTE-ACS）包括不稳定型心绞痛和非ST段抬高型心肌梗死的临床实体。在过去十年中取得了多项进展，包括新型抗血小板和抗血栓治疗方法的出现以及新的治疗策略，这使得死亡率显著降低。然而，由于高敏肌钙蛋白的使用以及心血管危险因素的增加，NSTE-ACS的发病率也有所上升。本文重点介绍了当代针对ACS患者的抗血小板、抗血栓和抗缺血治疗以及血运重建策略的管理策略更新。
